Abstract
During the six years since the Aum Shinrikyo cult's nerve gas attack on the Tokyo subway system, the United States has undertaken a major effort to prevent and respond to terrorist acts involving nuclear, radiological, biological and chemical weapons. Given this high level of official activity, it is remarkable that Aum's protracted and costly, but ultimately unsuccessful, attempts to acquire and use mass-casualty biological agents has received scant analytical attention. Specifically, there has been relatively little focus on one critical question: Why did this apparently sophisticated and lavishly funded program ultimately fail? Aum's failure suggests that it may, in fact, be far more difficult to carry out a deadly bioterrorism attack than has sometimes been portrayed by government officials and the press. Despite its significant financial resources, dedicated personnel, motivation, and freedom from the scrutiny of the Japanese authorities, Aum was unable to achieve its objectives. The Aum case illustrates how acquiring virulent strains of biological agents can be a major hurdle for prospective bioterrorists. Cult-like terrorist organizations, the ones that appear to have the greatest interest in mass-casualty biological weapons, may be least suited to meet the complex demands associated with a bioweapon program. As the Aum example illustrates, a paranoid, fantasy-prone and sometimes violent atmosphere is not conducive to the sound scientific judgement needed to produce mass-casualty biological weapons.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.